Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 2/2011

01.02.2011 | Review Article

Inactivated Influenza Vaccines

Recent Progress and Implications for the Elderly

verfasst von: Valentina Parodi, Daniela de Florentiis, Mariano Martini, Professor Filippo Ansaldi

Erschienen in: Drugs & Aging | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The current public health strategy for the containment of influenza is annual vaccination, which is recommended for the elderly and for those in risk factor categories that present the highest morbidity and mortality. However, because the immune response in the elderly is known to be less vigorous than in younger adults, research in the last decade has focused on improving the immune response to vaccination and increasing the protection of aged populations.
The decreased efficacy of vaccines in the elderly is due to several factors, such as a decrease in the number of Langerhans cells, the limited capacity of dendritic cells to present antigen, defects in the expression of Toll-like receptors and the reduced expression of MHC class I and II molecules. Also, production of mature naive T cells by the thymus decreases with age.
Among several approaches proposed to address the need for more immunogenic vaccines compared with conventional agents, the most well proven is the use of adjuvants.
The first licensed adjuvant, aluminium-based mineral salts (alum), introduced in the 1920s, remains the standard worldwide adjuvant for human use and it has been widely used for almost a century. However, the addition of alum adjuvant to a split or subunit influenza vaccine has induced only marginal improvements. Other adjuvants have been developed and approved for human use since 1997; in particular, MF59, an oil-in-water adjuvant emulsion of squalene, which is able to increase immunogenicity of seasonal, prepandemic and pandemic subunit vaccines while maintaining acceptable safety and tolerability profiles. More recently, another oil-in-water emulsion, AS03, has been approved as a component of pre-pandemic H5N1 and pandemic H1N1 2009 vaccines.
Besides adjuvants, several other strategies have been assessed to enhance antibody response in the elderly and other less responsive subjects, such as high-dose antigen vaccines, carrier systems (liposomes/virosomes) and the intradermal route of immunization. In particular, the potential of intradermal vaccination is well documented and the recent availability of an appropriate injection system, which combines simplicity, safety and ease of use, has allowed evaluation of the tolerability, safety and immunogenicity of the intradermal influenza vaccine in large numbers of subjects. Data that emerged from large clinical trials showed an improved immunogenicity compared with that of standard vaccine.
Observational studies or comparisons between adjuvanted, intradermal or high-dose versus conventional vaccines are needed to evaluate whether the greater immunogenicity observed in a number of recent studies is correlated with greater protection against influenza and influenza-related complications and death.
Literatur
1.
Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010; 50(5): 747–51PubMed
2.
Zambon MC, Stockton JD, Clewley JP, et al. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001; 358(9291): 1410–6PubMedCrossRef
3.
Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009; 27(37): 5043–53PubMedCrossRef
4.
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289(2): 179–86PubMedCrossRef
5.
Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis 2010; 10: 162PubMedCrossRef
6.
7.
Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348(14): 1322–32PubMedCrossRef
8.
Fleming DM, Cross KW, Pannell RS. Influenza and its relationship to circulatory disorders. Epidemiol Infect 2005; 133(2): 255–62PubMedCrossRef
9.
Fiore AE, Shay DK, Broder K, et al. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7): 1–60PubMed
10.
Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35(4): 370–7PubMedCrossRef
11.
Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24(8): 1159–69PubMedCrossRef
12.
Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46(7): 1078–84PubMedCrossRef
13.
Renshaw M, Rockwell J, Engleman C, et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002; 169(9): 4697–701PubMed
14.
Aspinall R, Del Giudice G, Effros RB, et al. Challenges for vaccination in the elderly. Immun Ageing 2007; 4: 9–12PubMedCrossRef
15.
Ritter MA, Palmer DB. The human thymic microenvironment: new approaches to functional analysis. Semin Immunol 1999; 11(1): 13–21PubMedCrossRef
16.
Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396(6712): 690–5PubMedCrossRef
17.
Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005; 26(7): 360–6PubMedCrossRef
18.
de Jong JC, Beyer WE, Palache AM, et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61(1): 94–9PubMedCrossRef
19.
de Jong JC, Palace AM, Beye WE, et al. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115: 63–73
20.
Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24(16): 3063–5PubMedCrossRef
21.
Kojimahara N, Maeda A, Kase T, et al. Cross-reactivity of influenza A(H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24(33-34): 5966–9PubMedCrossRef
22.
Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26(12): 1525–9PubMedCrossRef
23.
Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27(25-26): 3345–8PubMedCrossRef
24.
Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28(25): 4123–9PubMedCrossRef
25.
Glenny AT, Pope CG, Waddington H, et al. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29: 31–40CrossRef
26.
Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003; 8(20): 934–43PubMedCrossRef
27.
Dupuis M, Murphy TJ, Higgins D, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998; 186(1): 18–27PubMedCrossRef
28.
Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30(1): 23–32PubMedCrossRef
29.
Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105(30): 10501–6PubMedCrossRef
30.
Schultze V, D’Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008; 26(26): 3209–22PubMedCrossRef
31.
Harandi AM, Medaglini D, Shattock RJ, et al. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010; 28(12): 2363–6PubMedCrossRef
32.
Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27(25-26): 3331–4PubMedCrossRef
33.
Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367(9523): 1657–64PubMedCrossRef
34.
Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197(5): 667–75PubMedCrossRef
35.
Brady RC, Treanor JJ, Atmar RL, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009; 27(37): 5091–5PubMedCrossRef
36.
Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I—II randomized clinical trial. J Infect Dis 2008; 198(9): 1309–16PubMedCrossRef
37.
Vajo Z, Tamas F, Sinka L, et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375(9708): 49–55PubMedCrossRef
38.
Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375(9708): 56–66PubMedCrossRef
39.
Cvjetanovic B, Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines. Bull WHO 1965; 32: 29–36PubMed
40.
Bomford R. Aluminium salts: perspective in their use as adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. New York: Plenum Publishing Corp., 1989: 35–71CrossRef
41.
42.
Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19(17–19): 2673–80PubMedCrossRef
43.
44.
Del Giudice G, Fragapane E, Bugarini R, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13(9): 1010–3PubMedCrossRef
45.
Khurana S, Chearwae W, Castellino F, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2(15): 15ra5
46.
Huckriede A, Bungener L, ter Veer W, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003; 21(9–10): 925–31PubMedCrossRef
47.
Bungener L, Huckriede A, de Mare A, et al. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005; 23(10): 1232–41PubMedCrossRef
48.
Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 2003; 21(9–10): 921–4PubMedCrossRef
49.
Evison J, Farese S, Seitz M, et al. Randomized, doubleblind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48(10): 1402–12PubMedCrossRef
50.
Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal V: a virosomal adjuvanted influenza vaccine. Vaccine 2009; 27: 4381–7PubMedCrossRef
51.
de Bruijn IA, Nauta J, Gerez L, et al. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006; 24(44–46): 6629–31PubMedCrossRef
52.
Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010; 50(10): 1331–8PubMedCrossRef
53.
Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351(22): 2286–94PubMedCrossRef
54.
O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6(5): 699–710PubMedCrossRef
55.
Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21(11–12): 1268–74PubMedCrossRef
56.
Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49(3): 177–84PubMedCrossRef
57.
Li R, Fang H, Li Y, et al. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing 2008; 5: 2PubMedCrossRef
58.
Baldo V, Baldovin T, Floreani A, et al. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 2006; 21(11): 843–5PubMedCrossRef
59.
Baldo V, Baldovin T, Floreani A, et al., Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007; 27(5): 542–7PubMedCrossRef
60.
Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21(15): 1687–93PubMedCrossRef
61.
Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362(9400): 1959–66PubMedCrossRef
62.
Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191(8): 1210–5PubMedCrossRef
63.
64.
Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361(25): 2424–35PubMedCrossRef
65.
Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370(9587): 580–9PubMedCrossRef
66.
Baras B, Bouveret N, Devaster JM, et al. A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008; 2(6): 251–60PubMedCrossRef
67.
Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27(52): 7428–35PubMedCrossRef
68.
Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28(7): 1740–5PubMedCrossRef
69.
Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28(3): 849–57PubMedCrossRef
70.
Leroux-Roels I, Clement F, Leroux-Roels G, et al. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly [poster]. Influenza Vaccines for the World; 2006 Oct 18–20; Vienna
71.
Leroux-Roels I, Oostvogels L, Hons E, et al. Reactogenicity and safety of adjuvanted influenza vaccines administered in elderly [abstract plus poster]. Influenza Vaccines for the World; 2006 Oct 18–20; Vienna
72.
Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340: c2649PubMedCrossRef
73.
Carmona A, Omeñaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 2010; 28(36): 5837–44PubMedCrossRef
74.
Cryz SJ, Que JU, Glück R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996; 14(14): 1381–3PubMedCrossRef
75.
Felnerova D, Viret JF, Glück R, et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15(6): 518–29PubMedCrossRef
76.
Daemen T, de Mare A, Bungener L, et al. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57(3): 451–63PubMedCrossRef
77.
Glück R, Wegmann A. Influenza vaccination in the elderly. Dev Comp Immunol 1997; 21(6): 501–7PubMedCrossRef
78.
Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343(8893): 322–4PubMedCrossRef
79.
Glück R, Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 2003; 21(7–8): 611–5PubMedCrossRef
80.
de Bruijn IA, Nauta J, Gerez L, et al. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004; 103(1–2): 139–45PubMedCrossRef
81.
de Bruijn I, Meyer I, Gerez L, et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007; 26(1): 119–27PubMedCrossRef
82.
de Bruijn IA, Nauta J, Cramer WC, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005; 23Suppl. 1: S39–49PubMedCrossRef
83.
Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23Suppl. 1: S26–38PubMedCrossRef
84.
Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability ofa virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004; 23: 300–6PubMedCrossRef
85.
Baldo V, Menegon T, Bonello C, et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19(25–26): 3472–5PubMedCrossRef
86.
Pregliasco F, Mensi C, Serpilli W, et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001; 13(1): 38–43PubMed
87.
Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004; 32(4): 191–8PubMedCrossRef
88.
Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010: 517198PubMedCrossRef
89.
Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26(26): 3197–208PubMedCrossRef
90.
91.
Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198(5): 650–8PubMedCrossRef
92.
Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7(8): 1201–14PubMedCrossRef
93.
Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009; 27(52): 7304–12PubMedCrossRef
94.
Van Damme P, Arnou R, Kafeja F, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10: 134PubMedCrossRef
95.
Arnou R, Eavis P, Pardo JR, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years. Human vaccines 2010; 6: 346–54PubMedCrossRef
96.
Mostow SR, Schoenbaum SC, Dowdle WR, et al. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J 1973; 49: 152–8PubMedCrossRef
97.
Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166: 1121–7PubMedCrossRef
98.
Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 1972; 125: 656–64PubMedCrossRef
99.
Palache AM, Beyer WE, Sprenger MJ, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11: 3–9PubMedCrossRef
100.
Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25: 7656–63PubMedCrossRef
101.
Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657–64PubMedCrossRef
102.
Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343–51PubMedCrossRef
103.
Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375(9708): 41–8PubMedCrossRef
104.
Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged > or = 65 years (Fluzone High-Dose) and guidance for use — United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(16): 485–6
105.
Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years ofage and older. J Infect Dis 2009; 200: 172–80PubMedCrossRef
Metadaten
Titel
Inactivated Influenza Vaccines
Recent Progress and Implications for the Elderly
verfasst von
Valentina Parodi
Daniela de Florentiis
Mariano Martini
Professor Filippo Ansaldi
Publikationsdatum
01.02.2011
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2011
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11586770-000000000-00000

Weitere Artikel der Ausgabe 2/2011

Drugs & Aging 2/2011 Zur Ausgabe

Correspondencee

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting

Original Research Article

Association of Anticholinergic Drugs with Hospitalization and Mortality among Older Cardiovascular Patients

Original Research Article

Safety of Clopidogrel in Older Patients

Original Research Article

Once-Daily Trospium Chloride 60 mg Extended Release in Subjects with Overactive Bladder Syndrome Who Use Multiple Concomitant Medications

Review Article

Epidemiology, Pathophysiology and Medical Management of Postoperative Ileus in the Elderly

Original Research Article

Systemic Exposure to Armodafinil and Its Tolerability in Healthy Elderly versus Young Men

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise